tirzepatide

cancel
Biotech

Lilly withdraws phase 2 obesity trial before starting enrollment

The study was designed to test bimagrumab, an asset Lilly acquired in its $1.9 billion Versanis buyout, and blockbuster GLP-1/GIP drug tirzepatide.
Nick Paul Taylor Sep 25, 2025 8:07am
head to head against clash football helmets fight combat

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

Jun 23, 2025 2:30pm
pipelines in the sun

Lilly's next focus: Testing incretins in neuro, immunology fields

Feb 6, 2025 2:35pm
Close up of horse legs and hooves running on sand track

Biolexis enters small molecule into oral GLP-1 horse race

Sep 13, 2024 12:24pm
pond lilly pads

Arrowhead dips toes into obesity pond with 2 preclinical assets

Aug 14, 2024 3:50pm
baseball field pitch inning

The most valuable R&D projects? You guessed it: obesity

Jul 11, 2024 5:00am